Roche acquires Carmot Therapeutics’ valuable obesity and diabetes R&D in US$2.7 BN deal

05 Dec 2023 — Swiss-based Roche has secured a US$2.7 billion definitive merger agreement to acquire the private US company Carmot Therapeutics. This strategic merger brings forth a promising R&D portfolio, particularly focusing on incretins — gut hormones influencing insulin secretion and appetite suppression — with the potential to transform patient care in weight management.